ConductScience.org, home

Paper16580903

Comparison of midazolam and simvastatin as cytochrome P450 3A probes.

Chung E and 3 others. Clin Pharmacol Ther, 2006. Cited by 91 papers, by iCite.

Cite this record

ConductScience Library. Comparison of midazolam and simvastatin as cytochrome P450 3A probes. Papers, record 16580903. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/16580903

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Comparison of midazolam and simvastatin as cytochrome P450 3A probes.
PubMed
Journal
Clin Pharmacol Ther
PubMed
Year
2006
PubMed
Publication types
Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
91
iCite
Relative citation ratio, by iCite
3.2
iCite
Revised in PubMed
2015-11-19
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Chung EEllen
2Nafziger ANAnne N
3Kazierad DJDavid J
4Bertino JS JrJoseph S

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Anesthetics, IntravenousMajor topic
Anticholesteremic AgentsMajor topic
Cytochrome P-450 CYP3AMajor topic
MidazolamMajor topic
SimvastatinMajor topic
Administration, Oral
Adult
Area Under Curve
Cross-Over Studies
Female
Humans
Male

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT03145285Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical CarcinomaResults

Source ClinicalTrials.gov

Download CSV of trials

Cited by38

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 91 citations.

PMIDTitleJournalYearIn PapersSource
42717157Verification of a Physiologically-based Pharmacokinetic Model for Predicting CYP3A4-mediated Simvastatin and Simvastatin Acid Drug-drug Interactions.AAPS J2026https://conductscience.org/library/papers/42717157PubMed
41350955
Utilizing Physiologically Based Pharmacokinetic Modeling and Virtual Simulation for Simvastatin Tablets to Evaluate the Sensitivity of Using Parent vs Metabolite as Analyte on Bioequivalence Assessment.
AAPS J2025https://conductscience.org/library/papers/41350955PubMed
38840420Clinically important pharmacokinetic drug-drug interactions with antibacterial agents.Rev Esp Quimioter2024https://conductscience.org/library/papers/38840420PubMed
38689161The Use of Microdosing for In vivo Phenotyping of Cytochrome P450 Enzymes: Where Do We Stand? A Narrative Review.Eur J Drug Metab Pharmacokinet2024https://conductscience.org/library/papers/38689161PubMed
37162619Intraindividual Variability in Absolute Bioavailability and Clearance of Midazolam in Healthy Individuals.Clin Pharmacokinet2023https://conductscience.org/library/papers/37162619PubMed
34783193Physiologically-based pharmacokinetic modeling to predict CYP3A4-mediated drug-drug interactions of finerenone.CPT Pharmacometrics Syst Pharmacol2022https://conductscience.org/library/papers/34783193PubMed
34519068Evaluation of the drug-drug interaction potential of treosulfan using a physiologically-based pharmacokinetic modelling approach.Br J Clin Pharmacol2022https://conductscience.org/library/papers/34519068PubMed
34228545Model-Based Comparative Analysis of Rifampicin and Rifabutin Drug-Drug Interaction Profile.Antimicrob Agents Chemother2021https://conductscience.org/library/papers/34228545PubMed
33946131A generic framework for the physiologically-based pharmacokinetic platform qualification of PK-Sim and its application to predicting cytochrome P450 3A4-mediated drug-drug interactions.CPT Pharmacometrics Syst Pharmacol2021https://conductscience.org/library/papers/33946131PubMed
33687157Comprehensive PBPK model to predict drug interaction potential of Zanubrutinib as a victim or perpetrator.CPT Pharmacometrics Syst Pharmacol2021https://conductscience.org/library/papers/33687157PubMed
32543786Data Digitizing: Accurate and Precise Data Extraction for Quantitative Systems Pharmacology and Physiologically-Based Pharmacokinetic Modeling.CPT Pharmacometrics Syst Pharmacol2020https://conductscience.org/library/papers/32543786PubMed
32026490A Drug-Drug Interaction Study to Evaluate the Effect of TAS-303 on CYP3A Activity in the Small Intestine and Liver.J Clin Pharmacol2020https://conductscience.org/library/papers/32026490PubMed
30887238
Simulating the Impact of Elevated Levels of Interleukin-6 on the Pharmacokinetics of Various CYP450 Substrates in Patients with Neuromyelitis Optica or Neuromyelitis Optica Spectrum Disorders in Different Ethnic Populations.
AAPS J2019https://conductscience.org/library/papers/30887238PubMed
30260092A Strategy to Refine the Phenotyping Approach and Its Implementation to Predict Drug Clearance: A Physiologically Based Pharmacokinetic Simulation Study.CPT Pharmacometrics Syst Pharmacol2018https://conductscience.org/library/papers/30260092PubMed
30194612A Generic Model for Quantitative Prediction of Interactions Mediated by Efflux Transporters and Cytochromes: Application to P-Glycoprotein and Cytochrome 3A4.Clin Pharmacokinet2019https://conductscience.org/library/papers/30194612PubMed
30171692CYP3A4-mediated effects of rifampicin on the pharmacokinetics of vilaprisan and its UGT1A1-mediated effects on bilirubin glucuronidation in humans.Br J Clin Pharmacol2018https://conductscience.org/library/papers/30171692PubMed
30091221PBPK Models for CYP3A4 and P-gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin.CPT Pharmacometrics Syst Pharmacol2018https://conductscience.org/library/papers/30091221PubMed
29686151Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications.Antimicrob Agents Chemother2018https://conductscience.org/library/papers/29686151PubMed
29574682Human hepatocytes and cytochrome P450-selective inhibitors predict variability in human drug exposure more accurately than human recombinant P450s.Br J Pharmacol2018https://conductscience.org/library/papers/29574682PubMed
28910306A quantitative systems pharmacology approach, incorporating a novel liver model, for predicting pharmacokinetic drug-drug interactions.PLoS One2017https://conductscience.org/library/papers/28910306PubMed

See all 38 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
CYP3A41576PubTator's text mininghttps://conductscience.org/library/genes/1576

Source NCBI Gene

Download CSV of genes

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
ABIRATERONE ACETATECHEMBL271227Results1https://conductscience.org/library/drugs/CHEMBL271227

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • References
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/16580903

GET https://conductscience.org/api/papers/v1/16580903/cited_by?page=2